Interleukin4 (IL-4), also known as B cellstimulatory factor1, is a monomeric, approximately 13-18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1-3).It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four αhelix structure (4). Porcine IL-4 is synthesized with a 24 amino acid (aa) signal sequence. Mature porcine IL-4 shares 78%, 59%, 41%, and 41% aa sequence identity with bovine, human, mouse, and rat IL-4, respectively. Human IL-4 is active on porcine vascular endothelial cells (5). IL-4 exerts its effects through two receptor complexes (6, 7). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 Rα and the common γ chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and -21). The type II receptor on nonhematopoietic cells consists of IL-4Rα and IL13Rα1. The type II receptor also transduces IL-13 mediated signals. IL4 is primarily expressed by Th2biased CD4+ T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgE in B cells, acquisition of the Th2 phenotype by na?ve CD4+ T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (8, 11). IL-4 plays a dominant role in the development of allergic inflammation and asthma (10, 12).